Ginkgo Bioworks Holdings, Inc. (DNA) is a publicly traded Healthcare sector company. As of August 19, 2026, DNA trades at $6.60 with a market cap of $465.99M and a P/E ratio of -1.30. DNA moved -4.72% today. Year to date, DNA is -21.42%; over the trailing twelve months it is -52.68%. Its 52-week range spans $5.00 to $17.58. Analyst consensus is sell with an average price target of $9.00. Rallies surfaces DNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest DNA news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $6.60 |
| Market Cap | $465.99M |
| P/E Ratio | -1.30 |
| EPS | $-5.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.58 |
| 52-Week Low | $5.00 |
| Volume | 992.74K |
| Avg Volume | 0 |
| Revenue (TTM) | $111.86M |
| Net Income | $-290.80M |
| Gross Margin | 0.00% |
2 analysts cover DNA: 0 strong buy, 0 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is sell. Average price target: $9.00.